Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults

Rohtesh S. Mehta, Regis Peffault de Latour, Todd E. DeFor, Marie Robin, Aleksandr Lazaryan, Aliénor Xhaard, Nelli Bejanyan, Flore Sicre de Fontbrune, Mukta Arora, Claudio G. Brunstein, Bruce R. Blazar, Daniel J. Weisdorf, Margaret L. MacMillan, Gerard Socie, Shernan G. Holtan

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

We previously reported that bone marrow grafts from matched sibling donors resulted in best graft-versus-host disease-free, relapse-free survival at 1-year post allogeneic hematopoietic cell transplantation. However, pediatric patients comprised the majority of bone marrow graft recipients in that study. To better define this outcome in adults and pediatric patients at 1- and 2-years post- allogeneic hematopoietic cell transplantation, we pooled data from the University of Minnesota and the Hôpital Saint-Louis in Paris, France (n=1901). Graft-versus-host disease-free, relapse-free survival was defined as the absence of grade III-IV acute graft-versus-host disease, chronic graft-versus-host disease (requiring systemic therapy or extensive stage), relapse and death. In adults, bone marrow from matched sibling donors (n=123) had best graft-versus-host disease-free, relapse-free survival at 1- and 2-years, compared with peripheral blood stem cell from matched sibling donors (n=540) or other graft/donor types. In multivariate analysis, peripheral blood stem cells from matched sibling donors resulted in a 50% increased risk of events contributing to graft-versus-host diseasefree, relapse-free survival at 1- and 2-years than bone marrow from matched sibling donors. With limited numbers of peripheral blood stem cell grafts in pediatric patients (n=12), graft-versus-host disease-free, relapse-free survival did not differ between bone marrow and peripheral blood stem cell graft from any donor. While not all patients have a matched sibling donor, graft-versus-host disease-free, relapse-free survival may be improved by the preferential use of bone marrow for adults with malignant diseases. Alternatively, novel graft-versus-host disease prophylaxis regimens are needed to substantially impact graft-versus-host disease-free, relapse-free survival with the use of peripheral blood stem cell.

Original languageEnglish (US)
Pages (from-to)764-772
Number of pages9
JournalHaematologica
Volume101
Issue number6
DOIs
StatePublished - May 31 2016

Fingerprint Dive into the research topics of 'Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults'. Together they form a unique fingerprint.

  • Cite this